RxDoctor Payments Data

Viktoriya Nelson, MD

Internal Medicine · Ojai, CANPI 1619093143

Payments from drug & device makers

$988in general payments, 2019–2025

Across 51 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$271
  • Lilly USA, LLC$145
  • Novo Nordisk$132
  • Corcept Therapeutics$116
  • Merck$74
  • GSK$40
  • plus $210 from 9 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$988 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$101,250
Medicare patients
140
Services billed
2,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$116,967
MounjaroTirzepatide49$53,969
EliquisApixaban25$26,887
JardianceEmpagliflozin24$21,140
VraylarCariprazine Hcl13$17,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,474
FarxigaDapagliflozin Propanediol16$11,492
LinzessLinaclotide12$10,967
JanuviaSitagliptin Phosphate16$10,932
Mesalamine14$10,163
MyrbetriqMirabegron15$7,459
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$4,988
Varenicline Tartrate23$4,034
Atorvastatin Calcium269$3,423
Omeprazole141$3,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$132$116,967102 claims
Lilly USA, LLCMounjaro$145$53,96949 claims
PfizerEliquis, Paxlovid$35$29,74638 claims
AbbVieVraylar, Linzess, Synthroid$271$29,26157 claims
Boehringer IngelheimJardiance$27$21,14024 claims
AstraZenecaFarxiga, Symbicort$38$14,53327 claims
GSKTrelegy Ellipta$40$13,47412 claims
MerckJanuvia$74$10,93216 claims
Astellas Pharma US IncMyrbetriq$20$7,45915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Ojai

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →